Evaluation of the Association between Lithium Treatment and GSK-3? Polymorphism in Bipolar Disorder Patients

Basit Öğe Kaydı
dc.authoridince, bahri/0000-0001-5000-9845
dc.authoridGuloksuz, Sinan/0000-0002-6626-1874
dc.contributor.authorAltinbas, Kursat
dc.contributor.authorYesilbas, Dilek
dc.contributor.authorInce, Bahri
dc.contributor.authorCansiz, Alparslan
dc.contributor.authorSılan, Fatma
dc.contributor.authorÖzdemir, Öztürk
dc.contributor.authorGuloksuz, Sinan
dc.date.accessioned2025-01-27T20:34:35Z
dc.date.available2025-01-27T20:34:35Z
dc.date.issued2018
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: There is a lack of evidence regarding clinical predictors for the treatment response to lithium, which is the main stay treatment option for bipolar disorder. Studies that examined the mechanistic action of lithium revealed that glycogen synthase kinase 3 beta (GSK-3 beta) enzymeinhibition was important in regard to treatment responses. Based on this background, we aimed to investigate the association between responses to lithium treatment and five different polymorphisms of GSK-3 beta. Method: Lithium treatment response scale (LTRS) scores for 100 patients diagnosed with bipolar disorders type I were calculated according to the hospital records. Blood samples were collected and genomic DNA was obtained using the MagNA Pure Compact automatic isolation method. The GSK-3 beta: rs17183904, rs17183897, rs34009575, rs34002644, and rs17183890 polymorphisms were analyzed by real time PCR. Results: In this cohort, the mean age of patients was 41.1 +/- 10.3 years, the mean age of disease onset was 24.5 +/- 8.2, and the mean LTRS score was 4.9 +/- 1.8. There was no statistically significant difference for LTRS scores between groups in terms of gender, marital status, level of education, and the type of first episode. LTRS was significantly higher in only the patients harbouring GSK-3 beta rs17183890 AG genotype (p=0.008, t: 2.71). Interestingly, no differences were found for the remaining polymorphisms. Conclusion: The specific GSK-3 beta polymorphism that associated with lithium-response in our study may help to predict lithium responses and to develop individualized treatment. We presume that our pharmacogenomic findings may also provide important contributions to the clinical practice in regard to future evaluation of the treatment adherence and side effects. To obtain these goals, further genome-wide scanning studies conducted on larger sample cohorts are required.
dc.identifier.doi10.5080/u20582
dc.identifier.endpage78
dc.identifier.issn1300-2163
dc.identifier.issue2
dc.identifier.pmid30215834
dc.identifier.scopus2-s2.0-85048396965
dc.identifier.scopusqualityQ3
dc.identifier.startpage73
dc.identifier.urihttps://doi.org/10.5080/u20582
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23366
dc.identifier.volume29
dc.identifier.wosWOS:000439417200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isotr
dc.publisherTurkiye Sinir Ve Ruh Sagligi Dernegi
dc.relation.ispartofTurk Psikiyatri Dergisi
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectBipolar disorders
dc.subjectlithium response
dc.subjectGSK-3 beta polymorphism
dc.titleEvaluation of the Association between Lithium Treatment and GSK-3? Polymorphism in Bipolar Disorder Patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu